Rheumatology Advance Access originally published online on March 9, 2005
Rheumatology 2005 44(5):670-676; doi:10.1093/rheumatology/keh584
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Persistent clinical response to the anti-TNF-
antibody infliximab in patients with ankylosing spondylitis over 3 years
1 Rheumatology Medical Center Ruhrgebiet, Herne, Ruhr-University Bochum, 2 University Medicine Berlin, Campus Benjamin Franklin, Herne, 3 German Rheumatism Research Center, Berlin, 4 Schlosspark Clinic, Berlin, 5 Charité Hospital, Humboldt University, Berlin, 6 Berlin-Buch Hospital, Berlin, 7 Ludwig Maximilians University, Munich, 8 Immanuel Hospital, Berlin, 9 Heinrich Heine University, Düsseldorf and 10 Medical University, Hannover, Germany.
Correspondence to: J. Braun, Rheumazentrum Ruhrgebiet, Landgrafenstr. 15, 44652 Herne, Germany. E-mail: J.Braun{at}Rheumazentrum-Ruhrgebiet.de
Objective. Infliximab, a monoclonal antibody against tumour necrosis factor 
(TNF-), is approved in Europe for the treatment of patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. This report provides analyses from a 3-yr extension study, as a follow-up to both the 1- and 2-yr open label extensions of the original 3-month randomized controlled trial of infliximab in patients with AS.
Methods. Of the 49 patients with AS who completed the second year of the study, 46 continued treatment with infliximab 5 mg/kg every 6 weeks up to week 156. The Bath AS Disease Activity Index (BASDAI), the Bath AS Functional Index, the Bath AS Metrology Index, patient's and physician's global assessments, quality of life (Short Form-36), C-reactive protein (CRP) and erythrocyte sedimentation rate were assessed throughout the study period.
Results. The improvement of signs and symptoms observed in the majority of the patients during the first and second year was sustained throughout the third year of the study. Forty-three patients (62% of the 69 patients enrolled at baseline and 93% of the patients who started the third year) completed week 156. In the intention-to-treat analysis, an ASAS ‘5 out of 6’ and ASAS 40% response was seen by 46% and 50% of the patients, respectively. The scores for other efficacy assessments were similar to the values observed at weeks 54 and 102. Median CRP levels remained low (1.5 mg/l at week 156). There were no relevant side-effects and no discontinuation because of drug-related adverse events during the third year of the study.
Conclusions. Patients with AS receiving infliximab for 3 yr showed a durable clinical response without loss of efficacy. Long-term infliximab treatment was well tolerated by patients in this study.
KEY WORDS: Ankylosing spondylitis, Infliximab, TNF-
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Braun and J. Sieper What is the most important outcome parameter in ankylosing spondylitis? Rheumatology, December 1, 2008; 47(12): 1738 - 1740. [Full Text] [PDF]
|
|
|
|
|
|
E. K. Li, J. F. Griffith, V. W. Lee, Y.-X. Wang, T. K. Li, K. K. Lee, and L.-S. Tam Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation Rheumatology, September 1, 2008; 47(9): 1358 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Pradeep, A. Keat, and K. Gaffney Predicting outcome in ankylosing spondylitis Rheumatology, July 1, 2008; 47(7): 942 - 945. [Full Text] [PDF]
|
|
|
|
|
|
A. C. Keat, K. Gaffney, A. K. Gilbert, C. Harris, and J. Leeder Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis Rheumatology, April 1, 2008; 47(4): 481 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Braun, X Baraliakos, J Listing, C Fritz, R Alten, G Burmester, A Krause, S Schewe, M Schneider, H Sorensen, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor {alpha} therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response Ann Rheum Dis, March 1, 2008; 67(3): 340 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Baraliakos, J. Listing, J. Brandt, H. Haibel, M. Rudwaleit, J. Sieper, and J. Braun Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-{alpha} antibody infliximab Rheumatology, September 1, 2007; 46(9): 1450 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Botteman, J. W. Hay, M. P. Luo, A. S. Curry, R. L. Wong, and B. A. van Hout Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom Rheumatology, August 1, 2007; 46(8): 1320 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M K de Vries, G J Wolbink, S O Stapel, E R de Groot, B A C Dijkmans, L A Aarden, and I E van der Horst-Bruinsma Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation Ann Rheum Dis, January 1, 2007; 66(1): 133 - 134. [Full Text] [PDF]
|
|
|
|
|
|
Y Yazici and H Yazici A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor {alpha} inhibitors Ann Rheum Dis, January 1, 2007; 66(1): 124 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Jois, J. Leeder, A. Gibb, K. Gaffney, A. Macgregor, M. Somerville, and D. G. I. Scott Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective Rheumatology, December 1, 2006; 45(12): 1566 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gossec, A. Le Henanff, M. Breban, E. Vignon, P. Claudepierre, V. Devauchelle, D. Wendling, E. Lespessailles, L. Euller-Ziegler, J. Sibilia, et al. Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up Rheumatology, July 1, 2006; 45(7): 859 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Massara, P. L. Cavazzini, and F. Trotta In SAPHO syndrome anti-TNF-{alpha} therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations Rheumatology, June 1, 2006; 45(6): 730 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Braun, J Davis, M Dougados, J Sieper, S van der Linden, D van der Heijde, and for the ASAS Working Group First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis Ann Rheum Dis, March 1, 2006; 65(3): 316 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sieper, X. Baraliakos, J. Listing, J. Brandt, H. Haibel, M. Rudwaleit, and J. Braun Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab Rheumatology, December 1, 2005; 44(12): 1525 - 1530. [Abstract] [Full Text] [PDF]
|
|